BioSpace News Archive

The demand within the global market for intraocular lenses has been rising on account of the rising cases of cataract across the world, finds Transparency Market Research.

Heart closure devices are used primarily to close any defect or an opening between both the sides of the heart.

The global market for cell culture protein surface coatings is slated to expand at a highly promising pace in the next few years, thanks to the vast rise in investments by governments and market players in stem cell research and development activities.

Transparency Market Research has published a new report titled, “Contrast Media Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”.

Gnubiotics Sciences SA, a Swiss biotech company pioneering novel microbiome targeted solutions for humans and companion animals, announced the allowance from the European Patent Office for its patent application 19812838.1.

Exact Sciences Corp. announced that company management will participate in the following virtual conferences and invited investors to participate by webcast.

Avalyn Pharma Inc., a biopharmaceutical company focused on development of improved therapies for life threatening pulmonary diseases, presented at the ISAM conference in Boise, Idaho , the results of the 24 week data of a Phase I/II clinical study of two dose regimens of AP01 in patients with idiopathic pulmonary fibrosis.

Synairgen announces results of in vitro studies showing antiviral activity of interferon beta against key SARS-CoV-2 variants

Pfizer Inc. announced that the first enrolled subjects have received their immunizations as part of a new study in adults ages 65 or older exploring the coadministration of the company’s 20-valent pneumococcal conjugate vaccine candidate following a booster dose of the Pfizer-BioNTech COVID-19 Vaccine, currently authorized by the Food and Drug Administration under an Emergency Use Authorization.

Protagonist Therapeutics, Inc. announced that the first human subject has been dosed in a Phase 1 study of PN-232, a novel oral interleukin-23 receptor antagonist peptide.